Healthcare Industry News: nanoparticles
News Release - February 2, 2011
NANOBIOTIX Appoints Dr Bernd Mühlenweg as Head of Business DevelopmentPARIS--(Healthcare Sales & Marketing Network)-- NANOBIOTIX, the leading nanomedicine company focused on cancer therapy, announced today that its team has completed a comprehensive executive research and appointed Bernd Mühlenweg, PhD, as Head of Business Development.
Based on his comprehensive experience Dr Mühlenweg will be responsible for ensuring sustainable corporate growth by establishing strategic corporate and business alliances.
Dr Laurent Levy, CEO and co-founder of the company says: “This is a pivotal time for Nanobiotix: we are confident that Bernd’s specific skills in license agreements, alliance management, development and commercialisation, will reinforce Nanobiotix’ leading role in the nanomedicine field. This partnership is intented to mark a major step towards realisation of most promising nanomedicine agenda for pharma industry.”
Dr. Mühlenweg comments: “Nanobiotix has developed a truly unique pipeline of products to address the various applications of radiotherapy in different types of cancer. I look forward to helping this talented team in the crucial next phase of the company’s growth. My goal is to make NanoXrayTM technology a first-in-class approach in oncology and to make it the physician’s choice for personalized and efficacious cancer treatment with low side effects”.
Dr Mühlenweg, 39, holds a PhD in Chemistry from the Technical University of Munich. He completed his education with a Leadership program at St. Galler Business School and several M&A and negotiation workshops. He was involved in the negotiation and execution of several license and commercialization agreements and has almost 10 years experience in the pharmaceutical business development field. Dr Mühlenweg is co-author of numerous publications and 2 patents. He is a member of the Pharma Licensing Club of Germany (Pharmalizenzclub) and of the Protection Rights and Technical Contracts Committee of BioDeutschland. Most recently, Bernd served as Director Business Development of Munich based WILEX AG where he contributed significantly to acheiving WILEX leadership position in developing cancer therapeutics and diagnostics.
About NanoXray Platform
Radiotherapy is the second most common treatment in cancer therapy, used in more than 50% of all cancer patients. It is known to be an effective treatment, however the impact of its physical effect is limited by the dose of radiation that healthy tissues will stand, resulting in a narrow therapeutic window, and leaving a huge space for improvement. Nanobiotix has developed a new class of therapeutics based on nanoparticles, NanoXray™ therapeutics. They consist of inert nanoparticles designed to enter tumor cells. Upon activation by a standard dose of radiation, they release a tremendous amount of energy that destroys cancer cells, whilst the surrounding healthy tissues are preserved and receive the same dose of radiation as in standard radiotherapy. By significantly enhancing the power of radiotherapy, they could change the clinical outcome of radiotherapy and may also enable radiotherapy to play a larger role as a curative treatment.
ABOUT NANOBIOTIX - www.nanobiotix.com
Paris, France, based, Nanobiotix is a nanomedicine company dedicated to the development of new treatments for cancer based on the combined application of nanotechnologies and biotechnologies. Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo that was incorporated in 2003 and has been primarily funded by leading European venture capital firms (Matignon Technologies, OTC Asset Management, Cap Decisif, Amorcage Rhone-Alpes, CIC Vizille; Masseran Gestion-CGE). With the development of numerous new compounds, Nanobiotix's objective is to increase its leading position in nanomedicine field. A major milestone and validation of Nanobiotix approach is its first-in-man clinical study of NanoXray™ therapeutics going to start shortly.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.